Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Researchers examined the association between moderate alcohol intake and specific cancer risks.

21 Aug 2023

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Scientists have developed a lymph node-targeted multi-epitope subunit vaccine that induces strong humoral and cellular immune responses against EBV in mice.

14 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

CDK9 inhibitors: A promising new treatment for hematological malignancies

A new research perspective was published in Oncotarget's Volume 14 on August 7, 2023, entitled, "CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies."

9 Aug 2023

Researchers uncover genetic machinery responsible for EBV-induced B cell growth transformation

B cells or B lymphocytes are an important part of the body's immune system. When healthy B cells are infected with the Epstein-Barr virus (EBV), they undergo growth transformation, a process that immortalizes B cells, leading to their uncontrolled proliferation.

7 Aug 2023

GEMINI test shows promise for early detection of lung cancer

Novel blood testing technology being developed by researchers at the Johns Hopkins Kimmel Cancer Center that combines genome-wide sequencing of single molecules of DNA shed from tumors and machine learning may allow earlier detection of lung and other cancers.

4 Aug 2023

CAR-T immune therapies could be effective against solid tumors

CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests.

3 Aug 2023

The impact of medicinal plants on the gut microbiome in cancer

Researchers evaluate the associations between medicinal plants, the gut microbiome, and cancer.

2 Aug 2023

NYU Langone Health included on the 2023-24 Honor Roll of top 20 hospitals

NYU Langone Health once again stands out in U.S. News & World Report's annual "Best Hospital" rankings for its unwavering commitment to exceptionalism, with its inclusion on the 2023-24 Honor Roll of the top 20 hospitals.

1 Aug 2023

UCSF Medical Center named to Honor Roll of nation's top hospitals

U.S. News & World Report ranks UCSF Health adult care among nation's top 10 hospitals in 7 specialties, Best in the West for neurology/neurosurgery and rheumatology.

1 Aug 2023

Tails on engineered T cells could help fight cancer

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.

27 Jul 2023

Two infusions of IL-15-expressing CAR NK Cells boost survival in lymphoma mouse models

A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.

26 Jul 2023

Addressing research gaps: The UK's efforts to study lung cancer in never smokers

Study aimed to understand the specific needs of lung cancer in never smokers (LCINS) patients.

25 Jul 2023

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

20 Jul 2023

Can a low-bacterial diet improve outcomes for neutropenic cancer patients?

Scientists have reviewed the existing literature to provide evidence of the effectiveness of the low-bacterial diet in neutropenic cancer patients.

20 Jul 2023

The causative role of age-associated pre-existing senescent cells on COVID-19 severity

Researchers investigated the role of senescent cells in the context of SARS-CoV-2 infection.

10 Jul 2023

New study shows circulating anti-insulin CD4 T cells reflect progression of anti-islet immunity

In a recent study published in Science Translational Medicine, researchers profile antigen-specific helper clusters of differentiation 4-positive (CD4+) T-lymphocytes to determine anti-islet autoimmunity among mice and humans.

9 Jul 2023

Medicaid expansion under the ACA linked to increased palliative care use

More people with advanced cancers in the United States received critical palliative care services, according to new findings by researchers at the American Cancer Society (ACS).

5 Jul 2023

Using a vaccine to boost the response of engineered T cells

Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.